Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries.

Bente Glintborg,Daniela Di Giuseppe,Johan Karlsson Wallman,Dan C Nordström,Bjorn Gudbjornsson,Merete Lund Hetland,Johan Askling,Gerdur Grondal, Tuulikki Sokka,Sella A Provan,Brigitte Michelsen,Eirik Klami Kristianslund,Lene Dreyer,Thorvardur Jon Love,Ulf Lindström

Annals of the rheumatic diseases（2023）

引用 3|浏览33

暂无评分

摘要

Uptake of newer b/tsDMARDs occurred mainly in biologic-experienced patients. Regardless of mode of action, only a minority of patients starting a second or later b/tsDMARD course remained on drug and achieved LDA. Superior outcomes for adalimumab indicate that the positioning of newer b/tsDMARDs in the PsA treatment algorithm remains to be established.

查看译文

关键词

biological therapy,epidemiology,spondylitis, ankylosing,tumor necrosis factor inhibitors

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要